In its currently use, patients previously diagnosed with ovarian cancer will have blood levels measured for CA-125 to indicate disease recurrence, monitor disease progression, response to treatment, or predict prognosis after treatment. The gene discussed is MUC16; the disease is ovarian carcinoma.